Literature DB >> 23968556

α1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates.

Uri Galili1.   

Abstract

BACKGROUND: Anti-Gal is the most abundant natural antibody in humans and Old World primates (apes and Old World monkeys). Its ligand, the α-gal epitope (Galα1-3Galβ1-4GlcNAc-R), is abundant in nonprimate mammals, prosimians and New World monkeys whereas it is absent in humans and Old World primates as a result of inactivation of the α1,3galactosyltransferase (α1,3GT) gene in ancestral Old World primates, as recent as 20-28 million years ago. Since anti-Gal has been a "forbidden" autoantibody for >140 million years of evolution in mammals producing α-gal epitopes it was of interest to determine whether ancestral Old World primates could produce anti-Gal once α-gal epitopes were eliminated, i.e. did they carry anti-Gal encoding immunoglobulin genes, or did evolutionary selection eliminate these genes that may be detrimental in mammals synthesizing α-gal epitopes. This question was studied by evaluating anti-Gal prodution in α1,3GT knockout (GT-KO) pigs recently generated from wild-type pigs in which the α-gal epitope is a major self-antigen.
METHODS: Anti-Gal antibody activity in pig sera was assessed by ELISA, flow cytometry and complement mediated cytolysis and compared to that in human sera.
RESULTS: The study demonstrates abundant production of the natural anti-Gal antibody in GT-KO pigs at titers even higher than in humans. The fine specificity of GT-KO pig anti-Gal is identical to that of human anti-Gal.
CONCLUSIONS: Pigs and probably other mammals producing α-gal epitopes carry immunoglobulin genes encoding anti-Gal as an autoantibody. Once the α-gal epitope is eliminated in GT-KO pigs, they produce anti-Gal. These findings strongly suggest that similar to GT-KO pigs, inactivation of the α1,3GT gene in ancestral Old World primates enabled the immediate production of anti-Gal, possibly as a protective antibody against detrimental microbial agents carrying α-gal epitopes.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  GT-KO pigs; anti-Gal; primate evolution; α-gal epitope; α1, 3galactosyltransferase

Mesh:

Substances:

Year:  2013        PMID: 23968556     DOI: 10.1111/xen.12051

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  12 in total

1.  Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs.

Authors:  C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector
Journal:  Am J Transplant       Date:  2014-06-06       Impact factor: 8.086

Review 2.  Significance of the evolutionary α1,3-galactosyltransferase (GGTA1) gene inactivation in preventing extinction of apes and old world monkeys.

Authors:  Uri Galili
Journal:  J Mol Evol       Date:  2014-10-15       Impact factor: 2.395

Review 3.  α-Gal Nanoparticles in Wound and Burn Healing Acceleration.

Authors:  Uri Galili
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

4.  A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.

Authors:  Yashdeep Phanse; Brenda R Carrillo-Conde; Amanda E Ramer-Tait; Scott Broderick; Chang Sun Kong; Krishna Rajan; Ramon Flick; Robert B Mandell; Balaji Narasimhan; Michael J Wannemuehler
Journal:  Sci Rep       Date:  2014-01-20       Impact factor: 4.379

Review 5.  The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation.

Authors:  Alfred Joseph Tector; Mathilde Mosser; Matthew Tector; Jean-Marie Bach
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 6.  Future Perspectives in Small-Diameter Vascular Graft Engineering.

Authors:  Panagiotis Mallis; Alkiviadis Kostakis; Catherine Stavropoulos-Giokas; Efstathios Michalopoulos
Journal:  Bioengineering (Basel)       Date:  2020-12-10

Review 7.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

8.  Generation of α1,3-galactosyltransferase and cytidine monophospho-N-acetylneuraminic acid hydroxylase gene double-knockout pigs.

Authors:  Shuji Miyagawa; Hitomi Matsunari; Masahito Watanabe; Kazuaki Nakano; Kazuhiro Umeyama; Rieko Sakai; Shuko Takayanagi; Toki Takeishi; Tooru Fukuda; Sayaka Yashima; Akira Maeda; Hiroshi Eguchi; Hiroomi Okuyama; Masaki Nagaya; Hiroshi Nagashima
Journal:  J Reprod Dev       Date:  2015-07-26       Impact factor: 2.214

9.  A standardized quantitative method for detecting remnant alpha-Gal antigen in animal tissues or animal tissue-derived biomaterials and its application.

Authors:  Yan Lu; Anliang Shao; Yongqiang Shan; Hongni Zhao; Ming Leiguo; Yongjie Zhang; Yinxi Tang; Wei Zhang; Yan Jin; Liming Xu
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

Review 10.  Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.

Authors:  Uri Galili
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.